U.S. markets open in 1 hour 55 minutes
  • S&P Futures

    4,559.25
    +14.75 (+0.32%)
     
  • Dow Futures

    35,477.00
    +88.00 (+0.25%)
     
  • Nasdaq Futures

    15,675.75
    +88.50 (+0.57%)
     
  • Russell 2000 Futures

    2,257.30
    +7.80 (+0.35%)
     
  • Crude Oil

    81.34
    -1.32 (-1.60%)
     
  • Gold

    1,801.20
    +2.40 (+0.13%)
     
  • Silver

    24.11
    -0.08 (-0.31%)
     
  • EUR/USD

    1.1617
    +0.0011 (+0.09%)
     
  • 10-Yr Bond

    1.5290
    0.0000 (0.00%)
     
  • Vix

    16.57
    +0.59 (+3.69%)
     
  • GBP/USD

    1.3743
    +0.0001 (+0.01%)
     
  • USD/JPY

    113.5190
    -0.2910 (-0.26%)
     
  • BTC-USD

    61,021.85
    +2,184.48 (+3.71%)
     
  • CMC Crypto 200

    1,467.80
    -6.53 (-0.44%)
     
  • FTSE 100

    7,235.50
    -17.77 (-0.24%)
     
  • Nikkei 225

    28,820.09
    -278.15 (-0.96%)
     

Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019

  • Oops!
    Something went wrong.
    Please try again later.
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HOUSTON, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Thursday, August 15, 2019 at 8:30 a.m. ET to report financial results for the second quarter ended June 30, 2019 and to provide a business overview.

To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time and refer to conference ID 3792557. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.

Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and is in the process of filing an IND for a Phase 1 clinical trial for solid tumors. The Company is also developing BP1002, which targets the Bcl-2 protein and is expected to be evaluated for the treatment of lymphoma and solid tumors. In addition, BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3, is expected to enter Phase 1 studies in 2020.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369